Glucagon‐like peptide‐1 receptor agonist treatment associated weight fluctuation and influencing factors in patients with overweight or obesity
Jingxuan Wang(Peking University), Linong Ji(Peking University), Yuteng Yang(Peking University), Wenjia Yang(Peking University), Tingyang Wei(Peking University), Chu Lin(Peking University), Yuan Wang(Peking University), Yiran Wang(Peking University), Fang Lv(Liaoning Normal University), Changjie Tie(Peking University), Xiaoling Cai(Peking University)
Cited by 2
Related Papers
Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations
|Diabetes Care|2016|969
Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC
|Journal of Thoracic Oncology|2020|415
Impact of age at type 2 diabetes mellitus diagnosis on mortality and vascular complications: systematic review and meta-analyses
|Diabetologia|2020|373
Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial
|Nature Medicine|2024|152
Luteolin-loaded solid lipid nanoparticles synthesis, characterization, & improvement of bioavailability, pharmacokinetics in vitro and vivo studies
|Journal of Nanoparticle Research|2014|128